A Multifaceted GABA<sub>A</sub> Receptor Modulator: Functional Properties and Mechanism of Action of the Sedative-Hypnotic and Recreational Drug Methaqualone (Quaalude)


Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark (H.H., L.B., K.H.-J., A.A.J.); NeuroProof, Rostock, Germany (B.M.B., C.E., O.H.-U.S., A.G.-V.); and H. Lundbeck A/S, Valby, Denmark (C.B., J.F.B.)

Received March 29, 2015; accepted June 8, 2015

ABSTRACT

In the present study, we have elucidated the functional characteristics and mechanism of action of methaqualone (2-methyl-3-o-tolyl-4(3H)-quinazolinone, Quaalude), an infamous sedative-hypnotic and recreational drug from the 1960s–1970s. Methaqualone was demonstrated to be a positive allosteric modulator at human α<sub>1,2,3,5</sub>β<sub>2,3</sub>γ<sub>2S</sub> GABA<sub>A</sub> receptors (GABA<sub>A</sub>Rs) expressed in Xenopus oocytes, whereas it displayed highly diverse functionalities at the α<sub>4</sub>β<sub>2,3</sub>δ GABA<sub>A</sub>R subtypes, ranging from inactivity (α<sub>4</sub>β<sub>2,3</sub>δ) to positive allosteric modulation (α<sub>4</sub>β<sub>2,3</sub>δ, α<sub>6</sub>β<sub>2,3</sub>δ) or positive allosteric modulation (α<sub>4</sub>β<sub>2,3</sub>δ) to superagonism (α<sub>4</sub>β<sub>2,3</sub>δ). Methaqualone did not interact with the benzodiazepine, barbiturate, or neurosteroid binding sites in the GABA<sub>A</sub>R. Instead, the compound is proposed to act through the transmembrane β<sub>1</sub>/γ<sub>1</sub>/δ subunit interface of the receptor, possibly targeting a site overlapping with that of the general anesthetic etomidate. The negligible activities displayed by methaqualone at numerous neurotransmitter receptors and transporters in an elaborate screening for additional putative central nervous system (CNS) targets suggest that it is a selective GABA<sub>A</sub>R modulator. The mode of action of methaqualone was further investigated in multichannel recordings from primary frontal cortex networks, where the overall activity changes induced by the compound at 1–100 μM concentrations were quite similar to those mediated by other CNS depressants. Finally, the free methaqualone concentrations in the mouse brain arising from doses producing significant in vivo effects in assays for locomotion and anticonvulsant activity correlated fairly well with its potencies as a modulator at the recombinant GABA<sub>A</sub>Rs. Hence, we propose that the multifaceted functional properties exhibited by methaqualone at GABA<sub>A</sub>Rs give rise to its effects as a therapeutic and recreational drug.

Introduction

Methaqualone (2-methyl-3-o-tolyl-4(3H)-quinazolinone) has a colorful history as a therapeutic and recreational drug. Methaqualone was marketed in the early 1960s as a non-barbiturate hypnotic with a wide safety margin and low abuse potential under trade names like Quaalude, Parest, Somnafac, Revonal, and as the combination drug Mandrax (with the antihistamine diphenhydramine). In the subsequent years, methaqualone became one of the best-selling sedative-hypnotic drugs worldwide, with several structural analogs following in its trail (collectively referred to as “quaaludes”) (Carroll and Gallo, 1985; Gass, 2008). However, clinical use of the drug soon revealed that besides giving rise to serious adverse effects, it was highly addictive and induced tolerance and cross-tolerance with other hypnotics. Moreover, concomitantly with its therapeutic use, methaqualone became highly popular as a recreational drug, where it often was consumed in combination with alcohol (known as “luding out”) (Falco, 1976; McCarthy et al., 2005; Gass, 2008; Herzberg, 2011). These problems led to the implementation of tighter regulation of the drug, and by the mid-1980s, it had been withdrawn from most markets (Carroll and Gallo, 1985; Gass, 2008). Nevertheless, recreational use of illegally produced methaqualone still constitutes a substantial health problem in some parts of the world (Parry et al., 2004; McCarthy et al., 2005).

The overall clinical properties of methaqualone are very characteristic for a sedative-hypnotic drug; however, some of its in vivo effects differ from those induced by classic central nervous system (CNS) depressants. Methaqualone reportedly

This study was supported financially by the Novo Nordisk Foundation. The in vitro binding profiling of methaqualone was generously provided by the National Institute of Mental Health’s Psychoactive Drug Screening Program (NIMH PDSP) (Grant HHSN-271-2008-025C). The NIMH PDSP is directed by Bryan L. Roth at the University of North Carolina at Chapel Hill and project officer Jamie Driscol at NIMH, Bethesda, MD. dx.doi.org/10.1124/mol.115.099291.

ABBREVIATIONS: CNS, central nervous system; DS2, 4-chloro-N-[2-(2-thienyl)imidazo[1,2-a]pyridine-3-yl]benzamide; GABA<sub>A</sub>Rs, GABA<sub>A</sub> receptors; MEA, microelectrode array; MEST, maximal electroshock seizures threshold; MK801, (S)-N-[(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate; NAM, negative allosteric modulator; PAM, positive allosteric modulator; PDSP, Psychoactive Drug Screening Program; TEVC, two-electrode voltage clamp; WT, wild-type.
mediates a rapid induction of a more natural deep sleep that results in less severe dizziness/dullness and headaches in insomnia patients than benzodiazepines and barbiturates (Barcelo, 1961; Ionescu-Pioggia et al., 1988). Furthermore, unlike most sedatives, methaqualone is also quite efficacious as an antispasmodic (Gass, 2008). Finally, the euphoria and aphrodisiac properties constituting some of the major psychologic effects evoked by methaqualone in its recreational use are effects not typically associated with CNS depressants (Falco, 1976; Ionescu-Pioggia et al., 1988; Gass, 2008; Barceloux, 2012). Although the electroencephalographic effects induced by methaqualone in rodent and human brains largely resemble those produced by barbiturates and other CNS depressants, the fact that some qualitative differences have been observed between these drugs in these recordings seems to support the clinical observations (Pfeiffer et al., 1968; Saxena et al., 1977).

Whereas the therapeutic and psychotrophic effects of methaqualone arguably have been comprehensively documented, the molecular basis for these effects has never been investigated. Based on the overall similarities between its behavioral effects and those induced by barbiturates and benzodiazepines, methaqualone has been assumed to act through the GABA type A receptors (GABA_{AR}s) (Carroll and Galo, 1985; Gass, 2008). This family of ligand-gated anion mediators of the effects of these drugs, however, the link and Mody, 2012). The pentameric GABA_{AR} complex is typically composed of two subunits, and the receptor comprises numerous allosteric sites through which GABA-evoked signaling can be modulated by various drugs, including barbiturates, benzodiazepines, neurosteroids, and anesthetics (Sieghart, 2015). In contrast to the well-established role of GABA_{AR}s as the principal mediators of the effects of these drugs, however, the link between methaqualone and GABAergic neurotransmission is founded on strikingly sparse and largely inconclusive experimental data (Muller et al., 1978; Naik et al., 1978; Hicks et al., 1990).

In the present study, methaqualone has been subjected to an elaborate functional characterization at human GABA_{AR} subtypes expressed in *Xenopus* oocytes, and its molecular mechanism of action at the receptors has been delineated. Furthermore, the functionality of methaqualone at native GABA_{AR}s has been elucidated by multiparametric analysis of its electrophysiologic effects at cortical neuron network activity. Finally, the correlation between the functional properties of methaqualone at GABA_{AR}s in vitro and its in vivo efficacy in mice models for locomotion and anticonvulsant activity has been investigated.

### Materials and Methods

GABA, diazepam, ZnCl_{2}, and chemicals for buffers were obtained from Sigma-Aldrich (St. Louis, MO). Methaqualone (Fig. 1A) was synthesized by the MedChem Department at H. Lundbeck A/S. Pentobarbital and allopregnanolone were purchased from May and Baker (Dagenham, UK) and Merck Chemicals (Nottingham, UK), respectively. Flumazenil and etomidate were purchased from Abcam Biochemicals (Cambridge, UK), and DS2 (4-chloro-N-[2-(2-thienyl)imidazo[1,2-α]pyridine-3-y1 benzamide) was obtained from Tocris Cookson (Bristol, UK). Defolliculated stage V or VI oocytes harvested from female *Xenopus laevis* frogs (using MS222 as anesthetic) were obtained from Lohmann Research Equipment (Castrop-Rauxel, Germany).

### Molecular Biology

The subeloning of human α_{1-α_4}, β_1, β_2, β_3, δ, and γ_{2S} cDNAs into pcDNA3.1 has been described previously (Jensen et al., 2010; Hoestgaard-Jensen et al., 2014), and the human β_3 cDNA used in this study was in pGEMHE. Point mutations were introduced into cDNAs using the QuikChange mutagenesis kit (Stratagene, Santa Clara, CA) and oligonucleotides from TAG Copenhagen A/S (Copenhagen, Denmark). The integrity and the absence of unwanted mutations in all cDNAs created by polymerase chain reaction were verified by DNA sequencing (Eurofins MWG Operon, Ebersberg, Germany).

### Xenopus laevis Oocytes and Two-Electrode Voltage Clamp Recordings

The functional characterization of methaqualone at wild-type (WT) and mutant GABA_{AR}s expressed in *Xenopus* oocytes was performed essentially as previously described (Hoestgaard-Jensen et al., 2013). The GABA_{AR} cDNAs were linearized and applied as templates for in vitro cRNA synthesis using the T7 mMESSAGE mMACHINE High Yield Capped RNA transcription kit (Life Technologies Corp., Carlsbad, CA). Either 9 or 18 nl cRNA encoding for α_{1β_2} (α:β_2 ratio: 0.06:0.06 μg/μl) and α_{1γ_{2S}β_2γ_{2S}} GABA_{AR}s (α:β_2:γ_{2S} ratio: 0.01:0.01:0.01 μg/μl) or 46 nl cRNA encoding for α_{2β_2} (α:β_2 ratio: 1:0.1 μg/μl) and α_{4β_2β_2β_2} GABA_{AR}s (α:β_2 ratio: 1:0.1:1 μg/μl) were injected into oocytes, which subsequently were incubated at 18°C in modified Barth’s solution [88 mM NaCl, 1 mM KCl, 15 mM HEPES (pH 7.5), 2.4 mM CaCl_{2}, 0.1 mM MgCl_{2}, 0.1 mM MgSO_{4}, 0.3 mM CaCl_{2}, 100 U/ml penicillin and 100 μg/ml streptomycin]. Whole-cell currents in the α_{2β_2γ_{2S}β_2γ_{2S}} and α_{4β_2β_2β_2β_2} expressing oocytes were measured 1–4 and 3–6 days after cRNA injection, respectively. In the two-electrode voltage-clamp (TEVC) recordings, the oocytes were placed in a recording chamber continuously perfused with a saline solution [115 mM NaCl, 2.5 mM CaCl_{2}, 10 mM HEPES (pH 7.5), 1.8 mM CaCl_{2}, 0.1 mM MgCl_{2}], and the compounds tested were applied in the perfusate. Both voltage and current electrodes were agar-plugged with 3 M KCl and displayed resistances between 0.5–2.0 MΩ. Oocytes were voltage-clamped at −40 mV to −80 mV (depending on the current size) using an Oocyte Clamp OC-725C amplifier (Warner Instruments, Hamden, CT). The incorporation of the γ_{2S} subunit into the GABA_{AR}s assembled at the cell surface of α_{1β_2γ_{2S}β_2γ_{2S}} expressing oocytes was confirmed on a routine basis with 100 μM ZnCl_{2} (Karim et al., 2013), and the presence of δ in cell-surface-expressed receptors in α_4β_2β_2δ-injected oocytes was verified using the δ-GABA_{AR} selective positive allosteric modulator (PAM) DS2 (1 μM) and 1 μM ZnCl_{2} (Storustovu and Ebert, 2006; Wafford et al., 2006; Karim et al., 2012).

In the experiments where the functional properties of GABA or methaqualone as agonists at the various receptors were characterized, 10 μM GABA was applied to the perfusate until the peak of the response was observed, usually within 30 seconds. When two consecutive applications of GABA had elicited responses of comparable sizes (±5%), various concentrations of GABA or methaqualone were applied. In the experiments where the functional properties of various allosteric modulators were characterized, the GABA concentration used (GABA EC_{10} or GABA EC_{40–70}) was determined on the day of the experiment by measurements on two oocytes expressing the specific receptor. Subsequently, when two consecutive applications of GABA EC_{10} or GABA EC_{50–70} were applied to the perfusate and observed to elicit currents of comparable sizes (±5%), the functional characteristics of the allosteric modulators at the GABA_{AR}s were determined.
were determined by preapplication of the modulator to the perfusate 30 seconds before coapplication of the modulator and GABA. In all recordings, a 2.5-minute wash was executed between all applications to prevent receptor desensitization. At the end of each recording on an oocyte, a GABA concentration evoking the maximum response through the specific receptor was applied in the perfusate. Experiments were performed at room temperature, and each data point represents the mean ± S.E.M. value of recordings performed on at least three oocytes from at least two different batches of oocytes.

The recorded baseline-to-peak current amplitudes were analyzed using Clampfit 10.1 (Axon Instruments, Union City, CA), and data for the test compounds were normalized to the maximal response elicited by GABA on each oocyte. Data analysis and statistical analysis were performed using Prism GraphPad, version 6.0a (GraphPad Software, Inc. La Jolla, CA). Concentration-response and concentration-inhibition curves were fitted by nonlinear regression using the equation for a biphasic dose-response with variable slope. Comparison of best-fitting equation (monophasic versus biphasic) was carried out using the extra sum-of-squares F test, and the null hypothesis was rejected at \( P < 0.05 \). When a biphasic fit was the statistically better model, data were fitted to the equation for a biphasic dose-response curve using nonlinear regression. Unless otherwise stated in the figure legends, statistical analysis was performed using ordinary one-way analysis of variance. The null hypothesis was rejected at \( P < 0.05 \), and the differences between the means were analyzed by Dunnett’s multiple comparisons test with a single pooled variance.

### In Silico Study

The modeling study was performed using the software package MOE 2013.08 (Molecular Operating Environment, Chemical Computing Group, Montreal, QC, Canada) using the built-in mmff94x force field and the GB/SA continuum solvation model. Etomidate, loreclezole, and methaqualone were submitted to a stochastic conformational search (standard setup) to enumerate low-energy conformations. Structurally collapsed conformations were discarded, and superimposition of selected low-energy conformations (up to \( \Delta G = 3 \text{ kcal/mol} \)) was done using the built-in function by fitting the carbonyl groups of etomidate and methaqualone and the vinylogous chlorine of loreclezole.

### Screening of Methaqualone at Various CNS targets

In vitro binding profiling of methaqualone in competition radioligand binding assays at a total of 53 CNS targets were performed by the National Institute of Mental Health’s Psychoactive Drug Screening Program (PDSP). Detailed information about the binding assay protocols is given at http://pdsp.med.unc.edu/pdspw/binding.php. In brief, most of the binding assays were performed to homogenates of mammalian cell lines transiently or stably expressing the different targets, with a few assays being performed using homogenized rat brain tissue. Methaqualone was tested in an assay concentration of 30 \( \mu M \), and an assay concentration of the radioligand near or at the \( K_D \) value for the specific target was used. The functional characterization of methaqualone at GABAARs and at the \( \alpha_2\beta_2 \) nicotinic
acetylcholine receptor in fluorescence-based Ca\(^{2+}\)/Fluo-4 or membrane potential assays and at the human four GABA transporters in a conventional \[^{[H]}\]GABA uptake assay was performed essentially as described previously (Trattning et al., 2012; Hoestgaard-Jensen et al., 2014).

**Functional Phenotypic Characterization of Methaqualone at Neuronal Cell Cultures**

The effects of methaqualone at cortical network activity in vitro were characterized essentially as previously described for the opioid ligand LP1 (Parenti et al., 2013).

**Primary Cell Cultures.** Frontal cortex tissue was harvested from embryonic day 15/16 chr:NMRI mice (Charles River, Sulzfeld, Germany). The mice were sacrificed by cervical dislocation according to the German Animal Protection Act § 44. Tissue was dissociated by enzymatic digestion (133.3 Kunitz U/ml DNase, 10 U/ml papain) and mechanical trituration, counted, vitality-controlled, and plated in Dulbecco’s modified Eagle’s medium containing 5% fetal bovine serum and 5% horse serum on poly- D-lysine- and laminin-coated microelectrode array (MEA) neurochips with 64 passive electrodes (Center for Network Neuroscience, University of North Texas, Denton, TX). Cultures on the MEA chips were incubated at 37°C in a 10% CO\(_2\) atmosphere until ready for use, usually 4 weeks after seeding. Culture media were replenished twice a week with Dulbecco’s modified Eagle’s medium containing 10% horse serum. The developing cocultures were treated with the mitosis inhibitor 5-fluoro-2'-deoxyuridine (25 μM) and uridine (63 μM) for 48 hours on day 5 after seeding to prevent further glial proliferation. After 4 weeks in culture, the activity pattern stabilizes and is composed of one coordinated main burst pattern with several coordinated subpatterns (Gramowski et al., 2004, 2006a,b). In this study, cultures between 28 and 35 days in vitro were used.

**Multichannel and Data Analysis.** Extracellular recordings were performed using a computer-controlled 64-channel MEA workstation acquisition system (Plexon, Inc., Dallas, TX), where temperature control of 37°C and stable pH of 7.4 (10% CO\(_2\)) enabled stable recording and cumulative concentration-response determinations for periods longer than 10 hours (Parenti et al., 2013). The neuronal networks were acutely treated with a series of accumulating compound concentrations, a stable activity phase of the last 30 minutes was analyzed, and real-time unit separation and spike identification were performed in real-time as previously described (Parenti et al., 2013). Action potentials, termed spikes, were recorded as spike trains, which in cortical neurons are clustered in bursts (Gramowski et al., 2006a), and these were quantitatively described via direct spike train analysis using the programs NeuroEXplorer (Plexon Inc., Dallas, TX) and the proprietary tool NPWaveX. Bursts definition and high content analysis of the network activity patterns provided a multiparametric description characterizing the activity changes in four defined categories: overall activity, burst structure, oscillatory behavior and synchronicity (see Parenti et al., 2013) for more information). The parameters for each experiment and each experimental treatment were normalized to the corresponding values of the native reference activity. From each network, 21

**Pattern Recognition and Classification.** Characteristics of the effects displayed by methaqualone on the activity of cortical networks were elucidated further by analysis of the electrophysiologic data using methods of pattern recognition and cross validation as previously described (Parenti et al., 2013). A total of 204 spike train features were calculated using NPWaveX (NeuroProof GmbH, Rostock, Germany). Activity changes within these 204 features over the tested concentration range generate a functional, phenotypic profile for a compound. Methaqualone data were subsequently classified using pattern recognition (software package PatternExpert, NeuroProof GmbH) by comparison with the phenotypic profiles of 69 reference compounds from the NeuroProof database. An artificial neuronal network was trained with the datasets from the reference compounds to establish a classifier (multilayer feed forward network and back propagation algorithm without hidden units). It uses a multilayer feed-forward perceptron and a resilient-propagation learning algorithm that uses as many input nodes as features and one output node for each class that has to be classified. Relatively high variation in our data justifies nonuse of hidden layers. The thereby obtained cross-validation delivers a ranking that reflects the functional similarity between methaqualone data sets and reference compound. This analysis was repeated 10 times. The values reflect “% of methaqualone datasets classified as a phenotypic reference profile,” named the similarity score. High values reflect high functional phenotypic similarity between reference compound profiles and methaqualone.

**Animal Studies.**

**Animals.** Male NMRI mice (20–24 g at the time of testing) from Charles River (Germany) were housed under controlled conditions (12 hours of light starting at 06:00 hours, 20 ± 2°C, 30–70% humidity) in Macrolon (type III) cages, with standard sawdust bedding and environmental enrichment (plastic house and wooden chew blocks) and food and water available ad libitum. The experiments were carried out in accordance with the Danish legislation regulating animal experiments, Law and Order on Animal experiments; Act no. 474 of 15/05/2014 and Order no. 88 of 30/01/2013, and with the specific variation for this experiment issued by the National Authority.

**Maximal Electroshock Seizures Threshold and Beam Walk Assays.** Methaqualone was tested 60 minutes and diazepam 30 minutes after a subcutaneous dose in the beam walk assay, which is a sensitive measure of sedation or ataxia side effects. Briefly, mice walk across a wooden beam, 8 mm in diameter and 60 cm long, to a goal box at the far end. The number of foot slips and number of falls from the beam are scored (Stanley et al., 2005). The same mouse is first tested in beam walking, and then the convulsion threshold is determined by the maximal electroshock seizures threshold (MEST) to tonic hind limb extension by electrical stimulation via corneal electrodes using the ‘up and down’ method of shock titration (Kimball et al., 1957; Löscher and Schmidt, 1988). Electrical stimulation was delivered by electrical stimulator (Ellegaard Systems, Faaborg, Denmark) as constant current for 0.4 seconds at 50 Hz starting at 14 mA, and the stimulation intensity was lowered or raised by 2 mA steps if the preceding mouse did or did not show hind limb extension, respectively. In the same mouse, plasma and brain samples were taken to directly link efficacy to exposure.

**Plasma and Brain Exposure Analysis.** Mouse plasma and brain samples from the MEST study were analyzed for methaqualone using ultra-performance liquid chromatography followed by tandem mass spectrometry detection. Brain homogenate samples were prepared by homogenizing the brain 1:4 (v/v) with water: 2-propanol:dimethylsulfoxide (50:30:20 v/v/v), followed by centrifugation and collection of the supernatant. Sample preparation was performed by protein precipitation with acetonitrile, followed by centrifugation and the addition of 0.1% ammonium hydroxide. The mobile phase consisted of water/acetonitrile with ammonium hydroxide pumped through an analytical column (Acquity ultra performance liquid chromatography BEH phenyl column 1.8 μm, 2.1 × 30 mm, Waters, MA). Detection was performed using a Sciex-API 4000 MS (Applied Biosystems, The Netherlands) using electrospray with positive ionization mode with a parent > daughter molecular mass of 251.1 > 91.1 amu. The lower limit of quantification was 1 ng/ml in plasma and 5 ng/g in brain (peak S/N > 6). The free fraction of methaqualone was determined in vitro using standard equilibrium dialysis methods with freshly isolated mouse brain homogenate or plasma (Redrobe et al., 2012). Equilibrium dialysis was performed by incubating at 37°C for 5 hours in triplicate.
Results

Functional Characterization of Methaqualone at Human GABA\(_\text{A}\)Rs Expressed in Xenopus Oocytes

The functional properties of methaqualone were characterized at 13 human GABA\(_\text{A}\)R subtypes expressed in Xenopus oocytes by TEVC electrophysiology. Whereas GABA displayed monophasic concentration-response relationships at the most of these receptors, its concentration-response curves at the \(\alpha_4\beta_2\delta\) GABA\(_\text{A}\)R were distinctly biphasic, and recordings from \(\alpha_4\beta_3\delta\)-oocytes resulted in both monophasic and biphasic concentration-response curves (Table 1). In agreement with previous reports (Karim et al., 2012; Jensen et al., 2013; Hoestgaard-Jensen et al., 2014), the receptors formed in \(\alpha_4\beta_1\delta\)- and \(\alpha_4\beta_3\delta\)-expressing oocytes also exhibited pronounced levels of constitutive activity (assessed by application of 10 \(\mu\)M picrotoxin; unpublished data). All in all, these basic functional properties of the receptors were in good agreement with those obtained in previous studies (Mortensen et al., 2011; Karim et al., 2012, 2013; Hoestgaard-Jensen et al., 2013, 2014).

In the initial round of characterization, the functional properties of methaqualone were determined at \(\alpha_1\beta_2\gamma_2\delta\), \(\alpha_2\beta_2\gamma_2\delta\), \(\alpha_3\beta_2\gamma_2\delta\), \(\alpha_4\beta_2\delta\), \(\alpha_5\beta_2\gamma_2\delta\) and \(\alpha_6\beta_2\delta\) GABA\(_\text{A}\)Rs (Fig. 1). This selection of receptors not only represents the full spectrum of molecular diversity in terms of \(\alpha\)-subunits but also comprises six major physiologic GABA\(_\text{A}\)R subtypes (Olsen and Sieghart, 2008; Belletti et al., 2009; Brickley and Mody, 2012). Methaqualone displayed negligible agonism at the \(\alpha_{1,2,3,5}\beta_2\gamma_2\delta\) receptors (\(R_{\text{max}}\) values of 1–4% of GABA \(R_{\text{max}}\)), whereas it was more efficacious as an agonist at \(\alpha_2\beta_2\delta\) (\(R_{\text{max}}\) = S.E.M. = 5.5 ± 1.6; \(n = 5\)) and \(\alpha_4\beta_2\delta\) (\(R_{\text{max}}\) = S.E.M. = 13 ± 1.6; \(n = 8\)). In addition to its small intrinsic agonist activity, methaqualone was a PAM exhibiting micromolar concentration \(EC_{50}\) values at six receptors when coapplied with GABA EC\(_{10}\) (Fig. 1B; Table 1). The currents evoked by GABA EC\(_{10}\) in \(\alpha_1\beta_2\gamma_2\delta\), \(\alpha_2\beta_2\gamma_2\delta\), \(\alpha_3\beta_2\gamma_2\delta\), and \(\alpha_5\beta_2\gamma_2\delta\) oocytes were potentiated 6- to 8-fold by maximal potentiating concentrations of methaqualone. The compound was an even more efficacious PAM at the \(\alpha_4\beta_2\delta\) and \(\alpha_6\beta_2\delta\) GABA\(_\text{A}\)Rs, potentiating GABA EC\(_{10}\)-evoked currents through these receptors to amplitudes 2- to 3-fold greater than the maximal responses of GABA (Fig. 1B; Table 1). Interestingly, methaqualone displayed bell-shaped concentration-response curves as a PAM at all receptors when coapplied with GABA EC\(_{10}\) in concentrations ranging from 1 to 1000 \(\mu\)M (exemplified for

### Table 1

Functional properties of GABA and methaqualone determined by two-electrode voltage-clamp electrophysiology at human GABA\(_\text{A}\)Rs expressed in Xenopus oocytes

<table>
<thead>
<tr>
<th>GABA</th>
<th>EC(<em>{50}) (pEC(</em>{50}) ± S.E.M.)</th>
<th>Methaqualone</th>
<th>EC(<em>{50}) (pEC(</em>{50}) ± S.E.M.)</th>
<th>n</th>
<th>R(_{\text{max}}) ± S.E.M.</th>
<th>n</th>
</tr>
</thead>
<tbody>
<tr>
<td>(\alpha_1\beta_2)</td>
<td>7.8 (5.11 ± 0.05)</td>
<td>49 (4.31 ± 0.03)</td>
<td>79 ± 3.7</td>
<td>6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(\alpha_1\beta_2\gamma_2\delta)</td>
<td>57 (4.25 ± 0.10)</td>
<td>38 (4.41 ± 0.03)</td>
<td>84 ± 2.1</td>
<td>7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(\alpha_2\beta_2\gamma_2\delta)</td>
<td>34 (4.46 ± 0.18)</td>
<td>30 (4.52 ± 0.03)</td>
<td>77 ± 2.2</td>
<td>6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(\alpha_2\beta_2\gamma_2\delta)</td>
<td>40 (4.40 ± 0.07)</td>
<td>24 (4.61 ± 0.03)</td>
<td>75 ± 2.1</td>
<td>9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(\alpha_2\beta_2\gamma_2\delta)</td>
<td>120 (3.94 ± 0.03)</td>
<td>49 (4.31 ± 0.12)</td>
<td>66 ± 2.4</td>
<td>4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(\alpha_2\beta_2\gamma_2\delta)</td>
<td>0.46 (6.33 ± 0.44)</td>
<td>n.d.</td>
<td>n.d.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(\alpha_2\beta_2\gamma_2\delta)</td>
<td>0.034 (7.47 ± 0.54)</td>
<td>1.2 (5.91 ± 0.51)</td>
<td></td>
<td>4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(\alpha_2\beta_2\gamma_2\delta)</td>
<td>2.2 (5.65 ± 0.10)</td>
<td>68 (4.17 ± 0.06)</td>
<td>240 ± 27</td>
<td>5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(\alpha_2\beta_2\gamma_2\delta)</td>
<td>0.012 (7.94 ± 0.16)</td>
<td>3.1 (5.51 ± 0.14)</td>
<td></td>
<td>5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(\alpha_2\beta_2\gamma_2\delta)</td>
<td>31 (4.50 ± 0.06)</td>
<td>28 (4.56 ± 0.04)</td>
<td>73 ± 1.6</td>
<td>6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(\alpha_2\beta_2\gamma_2\delta)</td>
<td>1.4 (5.85 ± 0.08)</td>
<td>100 (−4.0)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(\alpha_2\beta_2\gamma_2\delta)</td>
<td>0.26 (6.54 ± 0.07)</td>
<td>74 (4.13 ± 0.02)</td>
<td>220 ± 25</td>
<td>4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(\alpha_2\beta_2\gamma_2\delta)</td>
<td>0.30 (6.52 ± 0.04)</td>
<td>36 (4.44 ± 0.04)</td>
<td>280 ± 22</td>
<td>8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(\alpha_2\beta_2\gamma_2\delta)</td>
<td>0.60 (6.23 ± 0.03)</td>
<td>31 (4.50 ± 0.04)</td>
<td>110 ± 21</td>
<td>7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(\alpha_2\beta_2\gamma_2\delta)</td>
<td>4.1 (5.39 ± 0.11)</td>
<td>88 (4.06 ± 0.03)</td>
<td>60 ± 4.8</td>
<td>4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(\alpha_2\beta_2\gamma_2\delta)</td>
<td>5.4 (5.26 ± 0.07)</td>
<td>25 (4.60 ± 0.22)</td>
<td>41 ± 2.6</td>
<td>5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(\alpha_2\beta_2\gamma_2\delta)</td>
<td>0.90 (6.05 ± 0.02)</td>
<td>96 (4.02 ± 0.03)</td>
<td>230 ± 24</td>
<td>5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(\alpha_2\beta_2\gamma_2\delta)</td>
<td>0.30 (6.53 ± 0.02)</td>
<td>230 (−3.5)</td>
<td></td>
<td>4</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

n.d., not determinable.

GABA displayed monophasic and biphasic concentration-response curves at three and four of seven \(\alpha_2\beta_2\delta\)-expressing oocytes, respectively. Methaqualone was tested as a positive and negative allosteric modulator at both oocyte populations.

Properties of methaqualone as an agonist at \(\alpha_2\beta_2\delta\) and \(\alpha_5\beta_2\gamma_2\delta\) GABA\(_\text{A}\)Rs. Agonist EC\(_{50}\) values are given in \(\mu\)M with pEC\(_{50}\) ± S.E.M. values in brackets, and \(R_{\text{max}}\) values are given in percentage of the \(R_{\text{max}}\) value of GABA at the receptor in indicates number of experiments performed.

The concentration-response curve was not completely saturated at the highest methaqualone concentration tested. EC\(_{50}\) (pEC\(_{50}\)) and \(R_{\text{max}}\) values have been extracted from the fitted curve.

Properties of methaqualone as a negative allosteric modulator at \(\alpha_4\beta_2\delta\) and \(\alpha_6\beta_2\delta\) GABA\(_\text{A}\)Rs determined in the presence of GABA EC\(_{40}\)-. Estimated IC\(_{50}\) values are given in \(\mu\)M with pIC\(_{50}\) in brackets.
αβ2γ2S and α6β2δ in Fig. 1, C and D). Furthermore, pronounced rebound currents were observed at methaqualone concentrations of 300 μM and greater (Fig. 1C).

To elucidate the nature of methaqualone-mediated modulation of αγ and αβδ GABAARs, GABA concentration-relationships at the α1β2γ2S and α6β2δ receptors were determined in the absence or presence of the modulator. In agreement with previous studies (Campo-Soria et al., 2006; Gielen et al., 2012), the maximal current amplitude evoked by GABA was not significantly reduced whereas the maximal response evoked by GABA was 0.08 (n = 4) (Fig. 1E). In contrast, preincubation and coapplication of 300 μM methaqualone increased the potency of GABA at the receptor by 41-fold [(EC50 (pEC50 ± S.E.M.) = 1.4 μM (5.85 ± 0.08) (n = 6) versus 57 μM (4.25 ± 0.10) (n = 7); P < 0.001), whereas the maximal response evoked by GABA was significantly reduced [Rmax ± S.E.M. = 82 ± 2.3% (n = 6); P < 0.1] (Fig. 1E). Interestingly, it was impossible to determine the effect of 300 μM methaqualone at the GABA concentration-response relationship at the α6β2δ receptor, since the large currents elicited through this receptor by coapplications of the modulator and high GABA concentrations consistently resulted in failure to keep the holding potential of the oocytes. However, low GABA concentrations unable to evoke significant currents in α6β2δ-oocytes when applied alone were observed to induce substantial currents when coapplied with 300 μM methaqualone (unpublished data). Thus, although we were unable to quantify the degree of left shift of the GABA concentration-response curve brought on by the presence of methaqualone, the drug clearly modulated both GABA potency and efficacy at this receptor.

With the first round of characterization having revealed distinctly different methaqualone functionalities at different α-containing GABAAR subtypes, the second round focused on the putative importance of β subunit identity and of the accessory γ2S/δ subunit for the modulation of α1β2γ2S and α4δδ GABAARs. The methaqualone-mediated potentiation of the α1β2γ2S GABAAR did not appear to be dependent on the presence of γ2S in the receptor, since the functionalities exhibited by the compound at α1β2 and α1β2γ2S Receptors did not differ significantly (Fig. 2A; Table 1). Furthermore, substituting β2 for β3 in the α1β2γ2S complex did not change the potency or efficacy of methaqualone as a PAM substantially (Fig. 2A; Table 1).

![Fig. 2](image-url) Functional properties of methaqualone at human GABAARs expressed in Xenopus oocytes. (A) Concentration-response curves for methaqualone at α1β2, α1β2γ2S, and α1β2γ2S GABAARs in the presence of GABA EC50 (means ± S.E.M.; n = 6–7). (B) Modulation of α6β2δ GABAAR signaling exerted by methaqualone in the presence of GABA EC10 or GABA EC50 (means ± S.E.M.; n = 4–8). (C) Representative trace and the concentration-response curve for methaqualone as an agonist at the α6β2δ GABAAR (means ± S.E.M.; n = 6). The gray application bars above the trace indicate application of the various methaqualone concentrations, and the black bar represents the application of a GABA concentration eliciting a maximal response. (D, left) Concentration-response curves for methaqualone at α6β2, α6β2δ, α6β2δ, and α6β2δ GABAARs in the presence of GABA EC10 (means ± S.E.M.; n = 4–6). (D, right) Concentration-inhibition curve for methaqualone at the α6β1δ GABAAR in the presence of GABA EC10 (means ± S.E.M.; n = 5). The hatched concentration-response curves for α6β2γ2S and α6β2δ in (A) and (D), respectively, are based on data displayed in Fig. 1B.
In contrast to its comparable modulation of \( \alpha_1\beta_2\gamma_2S \) and \( \alpha_1\beta_3\gamma_2S \) receptors, methaqualone displayed dramatically different functionalities at the different \( \beta \) subunit-containing \( \alpha_4\delta \) and \( \alpha_5\delta \) subtypes. Contrary to its PAM activity at the \( \alpha_1\beta_2\delta \) GABA\(_A\)R (Fig. 1B), methaqualone did not modulate the responses evoked by GABA EC\(_{10}\) or GABA EC\(_{70}\) in \( \alpha_4\delta\gamma \)-oocytes, and strikingly the presence of \( \beta_3 \) in the \( \alpha_4\delta\gamma \) complex converted the compound into a superagonist with an efficacy comparable to that of the orthosteric agonist THIP (4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol) (Fig. 2, B and C; Table 1) (Storustovu and Ebert, 2006; Hoestgaard-Jensen et al., 2014). The origin of the agonism mediated by methaqualone at this receptor will be addressed further in the Discussion section.

The functional properties exhibited by methaqualone at the three \( \alpha_4\delta\gamma \) GABA\(_A\)Rs were just as diverse as those at the \( \alpha_4\delta \) receptors, but interestingly the pattern of functionalities determined for the modulator at these two receptor groups differed completely (Table 1). Methaqualone was a less efficacious PAM at \( \alpha_4\delta\gamma \) than at \( \alpha_4\delta\gamma \) GABA\(_A\)Rs, and the compound did not potentiate the GABA-evoked signaling through the \( \alpha_4\beta\delta \) GABA\(_A\)R but instead acted as a weak negative allosteric modulator (NAM) at the receptor (Fig. 2D; Table 1). Finally, judging from the similar functional characteristics displayed by methaqualone at \( \alpha_4\beta_2 \) and \( \alpha_5\beta_2\delta \) GABA\(_A\)Rs, the presence of the \( \delta \) subunit in the GABA\(_A\)R assembly did not seem to be important for its modulation of \( \alpha\beta\delta \) receptors (Fig. 2D; Table 1).

**Delineation of the Mechanism of Action of Methaqualone at the GABA\(_A\)R**

To elucidate the molecular basis for methaqualone modulation of the GABA\(_A\)R, we investigated the putative interactions of the modulator with four known allosteric sites in the receptor complex.

**The Benzodiazepine Site.** The high-affinity benzodiazepine site in the \( \alpha\beta\gamma \) GABA\(_A\)R is located at the extracellular \( \alpha^+\gamma^+ \) subunit interface (Wieland et al., 1992; Sigel and Lüscher, 2011). Although the similar potencies displayed by methaqualone at the numerous GABA\(_A\)R subtypes included in this study suggested that the modulator does not act through this site, the different structure of methaqualone compared with benzodiazepines hypothetically could enable it to bind to the \( \alpha^+\gamma^+ \) interface in \( \alpha\beta\gamma \) receptors, as well as to the corresponding interfaces in \( \alpha\beta \) and \( \alpha\delta\gamma \) GABA\(_A\)Rs. This possibility was investigated by two different approaches.
In the first experiment, the effect of the benzodiazepine-site antagonist flumazenil on methaqualone-mediated potentiation of α1β2γ2S receptor signaling was assessed. In concordance with the literature (Sigel and Lüscher, 2011), preincubation and coapplication of 10 μM flumazenil with GABA EC10 did not modulate the agonist-evoked response through the receptor significantly (10 ± 1.4% (n = 13) versus 13 ± 1.3% (n = 13)), whereas the potentiation of the GABA EC10-evoked response mediated by 3 μM diazepam (31 ± 3.7%, n = 11) was completely eliminated by the presence of the antagonist (12 ± 1.4%, n = 6) (Fig. 3A). In contrast, 10 μM flumazenil did not reduce the methaqualone-mediated potentiation of α1β2γ2S GABAAR signaling significantly (59 ± 3.5% (n = 7) versus 61 ± 4.2% (n = 7)) (Fig. 3A).

In the second experiment, the impact of the α1-H102R mutation on the methaqualone-mediated modulation at α1β2γ2S receptor signaling was investigated. Substitution of this conserved histidine residue in the α1,2,3,5-subunit with an arginine (the corresponding residue in α4,6) has been shown to render α1,2,3,5/6 receptors insensitive to benzodiazepines (Wieland et al., 1992; Sigel and Lüscher, 2011). Whereas diazepam (3 μM) was completely inactive as a PAM at the α1H102β2γ2S GABAAR, the potentiation of GABA EC10 evoked-signaling through WT α1β2γ2S and α1H102β2γ2S receptors exerted by 300 μM methaqualone did not differ substantially (77 ± 2.1% (n = 6) versus 70 ± 2.1% (n = 5)) (Fig. 3B). In conclusion, these findings unequivocally rule out the high-affinity benzodiazepine site as the site of action for methaqualone.

The Barbiturate Site. Although numerous residues and regions in GABAARs have been shown to be important for the barbiturate-mediated modulation of the receptors, the exact location of the binding site(s) for these ago-PAMs in the receptors has yet to be identified (Serafini et al., 2000; Greenfield et al., 2002; Feng and Macdonald, 2010; Chiara et al., 2013). To assess whether methaqualone targets the barbiturate site or an overlapping site in the GABAAR, we investigated whether the small but significant agonist response evoked by 300 μM pentobarbital through the α1β2γ2S receptor could be modulated by methaqualone. As can be seen in Fig. 3C, the current amplitudes elicited by 300 μM methaqualone (1.2 ± 0.17%, n = 6) and by 300 μM pentobarbital (4.9 ± 0.68%, n = 6) at α1β2γ2S-expressing oocytes were significantly smaller than that arising from coapplication of the two compounds at the receptor (18 ± 1.7%, n = 6). The ability of methaqualone to potentiate pentobarbital-evoked α1β2γ2S signaling demonstrates that it binds to a site that does not overlap with the site through which the barbiturate mediates its direct activation of the receptor. However, in view of the presently limited insight into the molecular basis for barbiturate modulation of GABAARs, we cannot exclude the possibility that barbiturate-mediated potentiation could arise from a distinct site in the GABAAR and that this site could overlap with the methaqualone binding site.

The Neurosteroid Sites. Several endogenous and synthetic neurosteroids act as potent ago-PAMs of GABAARs (Herd et al., 2007). Smart and coworkers have proposed the existence of two discrete binding sites for neurosteroids in the transmembrane domains of the murine α1β2γ2S GABAAR: an intersubunit site at the β3′/γ2-subunit interface (comprising the α1-TM1 residue Thr236) important for neurosteroid activation and an intrasubunit site in the α subunit (comprising the α1-TM1 residue Gln242), which is important for both neurosteroid-mediated potentiation and activation (Hosie et al., 2006, 2009). To investigate whether methaqualone mediates its effects on GABAAR signaling through one or both of these sites, the impact of mutations of these two α1 residues (Thr236 and Gln242, human α1 numbering) on the modulation exerted by the compound at the α1β2γ2S GABAAR was determined. Allopregnanolone was used as reference compound in these recordings, and in concordance with previous studies, the neurosteroid was an efficacious PAM of the GABAAR (Fig. 3D). In contrast to previous findings, however, allopregnanolone did not exhibit significant intrinsic agonist activity at the receptor at concentrations up to 10 μM (Hosie et al., 2006, 2009; Chen et al., 2014). The possible reasons for the absence of the direct activation component of allopregnanolone at the receptor are currently being investigated in our laboratory.

The absence of allopregnanolone-evoked agonism at the α1β2γ2S receptor obviously precluded us from verifying the previously reported effects of α1-Q242W and α1-T237I mutations on this activity component of the neurosteroid. However, in agreement with the previously reported importance of a highly conserved Gln residue in TM1 of the α subunit for neurosteroid-mediated potentiation of GABAARs (Hosie et al., 2006, 2009), allopregnanolone was completely inactive as a PAM at the α1Q242Wβ2γ2S receptor at concentrations up to 10 μM (Fig. 3D). In contrast, the presence of 10 μM allopregnanolone potentiated GABA EC10-evoked currents in WT α1β2γ2S- and α1T237Iβ2γ2S-expressing oocytes to similar degrees, which is also in agreement with the findings by Hosie et al. (2006) and with the notion of the proposed intersubunit site being responsible for neurosteroid-mediated activation exclusively (Fig. 3D). Interestingly, the degree of potentiation of the GABA EC10-evoked response through the α1β2γ2S receptor mediated by 300 μM methaqualone was not changed significantly by the introduction of neither the Q242W nor the T237I mutation in the α1 subunit (Fig. 3D).

Although the functional implications of the two α1 mutations on allopregnanolone-mediated potentiation of the GABAAR observed in this study are in concordance with those reported by the Smart group, the apparent discrepancy between our findings and the literature when it comes to the intrinsic agonist activity of the neurosteroid should obviously be kept in mind when interpreting the results obtained for methaqualone in these recordings. We propose that the dramatically different effects induced by the α1-Q242W mutation on the allopregnanolone- and methaqualone-mediated potentiation of α1β2γ2S receptor signaling unequivocally demonstrate that methaqualone does not act through the proposed intrasubunit neurosteroid site in the receptor. As for the proposed intersubunit neurosteroid site, the lack of intrinsic agonist activity of allopregnanolone at α1β2γ2S clearly devalues it as a reference compound. Taken at face value, however, the WT-like properties exhibited by methaqualone at the α1T237Iβ2γ2S receptor does suggest that the modulator does not target a site comprising this residue.

The Transmembrane β3′/γ2-Subunit Interface. The transmembrane β3′/γ2 interface in the GABAAR harbors binding sites for numerous allosteric modulators, but with the exception of the site targeted by the general anesthetic etomidate.
the compositions and locations of these sites are poorly elucidated (Wafford et al., 1994; Belelli et al., 1997; Hill-Venning et al., 1997; Halliwell et al., 1999; Walters et al., 2000; Krasowski et al., 2001; Bali and Akabas, 2004; Thompson et al., 2004; Khom et al., 2007). Interestingly, however, several of these modulators exhibit distinct selectivity between GABA$_R$ subtypes on the basis of their respective $\beta$-subunits (Wafford et al., 1994; Belelli et al., 1997; Halliwell et al., 1999; Thompson et al., 2004; Khom et al., 2007). In this light, the differential functionalities displayed by methaqualone at the different $\beta$-subunit containing $\alpha_2\beta_3$ and $\alpha_6\beta_3$ receptors were intriguing and prompted us to probe the putative importance of three transmembrane residues in the GABA$_R$ for the functional properties of methaqualone.

Residue 265 in TM2 of the $\beta$-subunit ($\beta_2$-Ser$^{265}$, $\beta_3$-$\beta_3$-Asn$^{265}$) is a key molecular determinant of the $\beta$-selectivity ($\beta_2$/$\beta_3$-over-$\beta_1$ or $\beta_1$-over-$\beta_2$/$\beta_3$) displayed by several of the $\alpha/(\beta^+)$-interface modulators (Wingrove et al., 1994; Belelli et al., 1997; Hill-Venning et al., 1997; Halliwell et al., 1999; Khom et al., 2007). In the case of etomidate, the residue is believed not to participate in binding but rather to act as a transduction element between modulator binding and its effect on gating (Li et al., 2006; Desai et al., 2009; Chiara et al., 2012; Stewart et al., 2013; Stewart et al., 2014). In agreement with previous studies (Belelli et al., 1997; Siegwart et al., 1997; Desai et al., 2009; Stewart et al., 2013; Stewart et al., 2014), the introduction of a N265M mutation in $\beta_2$ eliminated etomidate-mediated potentiation of $\alpha_2\beta_2$ receptor signaling completely, and interestingly the mutation had a similar detrimental effect on GABA$_R$ signaling evoked by 100 $\mu$M etomidate or 300 $\mu$M methaqualone in the presence of GABA EC$_{10}$ (means $\pm$ S.E.M.; $n$ = 5) (Fig. 4).

**Fig. 4.** The potential interaction of methaqualone with the transmembrane $\beta$/$\beta^+$-subunit interface in the GABA$_R$ complex. The experiments were performed at human WT and mutant GABA$_R$s expressed in *Xenopus* oocytes. (A) Modulatory effects of 100 $\mu$M etomidate and 300 $\mu$M methaqualone on the responses evoked by GABA EC$_{10}$ through $\alpha_2\beta_2$/$\alpha_2\beta_2$-N265M, $\delta$ GABA$_R$s (means $\pm$ S.E.M.; $n$ = 3–14). Asterisks indicate significant differences between the responses evoked by GABA EC$_{10}$ in the presence of modulator and by GABA EC$_{10}$ alone at the same receptor: ****$P < 0.0001$. (B) Concentration-response curves for methaqualone at $\alpha_2\beta_2$ and $\alpha_2\beta_2$-N265M GABA$_R$s in the presence of GABA EC$_{10}$ (means $\pm$ S.E.M.; $n$ = 3–8). (C, left) Concentration-inhibition curves for methaqualone at $\alpha_2\beta_2$ and $\alpha_2\beta_2$-N265M GABA$_R$s in the presence of GABA EC$_{10}$ (means $\pm$ S.E.M.; $n$ = 3–8). (C, right) Direct activation of $\alpha_2\beta_2$/$\alpha_2\beta_2$-M286W GABA$_R$s (means $\pm$ S.E.M.; $n$ = 5). (D, left) Modulatory effects of 100 $\mu$M etomidate and 300 $\mu$M methaqualone on the responses evoked by GABA EC$_{10}$ at $\alpha_2\beta_2$ and $\alpha_2\beta_2$-M286W GABA$_R$s (means $\pm$ S.E.M.; $n$ = 4–8). Asterisks indicate significant differences between the responses evoked by etomidate or methaqualone at the two receptors: ****$P < 0.0001$ (unpaired two-sided t test). (D, right) Concentration-response curve for methaqualone as an agonist at the $\alpha_2$-$\beta_2$/$\alpha_2$-$\beta_2$-M286W GABA$_R$ (mean $\pm$ S.E.M.; $n$ = 4). (E, left) Modulatory effects of 100 $\mu$M etomidate and 300 $\mu$M methaqualone on the responses evoked by GABA EC$_{10}$ at $\alpha_2\beta_2$ and $\alpha_2\beta_2$-M286W GABA$_R$s (means $\pm$ S.E.M.; $n$ = 5–10). Asterisks indicate significant differences between the responses evoked by GABA EC$_{10}$ in the presence of modulator and by GABA EC$_{10}$ alone at the same receptor: ****$P < 0.0001$; ****$P < 0.0001$. (E, right) Concentration-response curves for methaqualone at $\alpha_2\beta_2$ and $\alpha_2\beta_2$-M286W GABA$_R$s (means $\pm$ S.E.M.; $n$ = 5–7). The hatched concentration-response curves for $\alpha_2\beta_2$ (B) $\alpha_2\beta_2$ (C) and $\alpha_2\beta_2$ (E) are based on data in Figs. 2D, 1B, and 1B, respectively.
the methaqualone-mediated potentiation (Fig. 4A). Furthermore, the PAM and NAM activities exhibited by methaqualone at the α4βδ and α2βδ receptors, respectively, were completely reversed by the introduction of the reciprocal residue in position 265 of the respective β subunits. In fact, methaqualone was roughly equipotent and equally efficacious as a PAM at the α4βδ and α2βδS265Gδ receptors and as a NAM at the α4βδS and α2βδN265Gδ receptors (Table 1).

Elaborate photolabeling, substituted cysteine accessibility method, and mutagenesis studies have demonstrated the key importance of the α1- or β1 TM1 Met236 and β2-TM3 Met296 residues for the GABAAR modulation exerted by etomidate, and the two residues are believed to form direct interactions with the modulator (Siegwart et al., 2002; Li et al., 2006; Stewart et al., 2008; Chiara et al., 2012; Stewart et al., 2013). In concordance with previous studies (Siegwart et al., 2002; Stewart et al., 2008), etomidate (100 μM) displayed higher intrinsic agonist activity at the α1M236Wβ2γ2S GABAAR than at the WT α1β2γ2S receptor, whereas it was completely inactive at the α1β2M286Wγ2S receptor (Fig. 4, D and E). Analogously to the increased intrinsic agonist activity of etomidate brought on by the α1-M236W mutation, the insignificant agonism of methaqualone at WT α1β2γ2S was converted into pronounced agonist activity at the α1M236Wβ2γ2S GABAAR (Fig. 4D). Conversely, the effect of the β2-M286W mutation on methaqualone functionality was considerably more subtle than that for etomidate, methaqualone being roughly equipotent albeit less efficacious as a PAM at the α1β2M286Wγ2S GABAAR compared with the WT receptor (Fig. 4E).

In a final experiment, we compared the modulation exerted by etomidate at the α4βδ GABAARs with the diverse functionalities exhibited by methaqualone at the three receptors. As mentioned previously, etomidate acts as a PAM at a plethora of α1,2,3,6βγ2 GABAARs, being ~10-fold more potent and substantially more efficacious at β2/β3-containing than at β1-containing subtypes of these receptors (Belelli et al., 1997; Hill-Venning et al., 1997). Etomidate has also been reported to potentiate GABA-evoked signaling through α4βδ GABAARs expressed in Xenopus oocytes and in mammalian cell lines (Brown et al., 2002; Meera et al., 2009; Jensen et al., 2013), but to our knowledge, its modulatory effects at recombinant α4βδ and α2βδ receptors have not been reported. Etomidate (100 μM) displayed no significant agonist activity at the receptors formed in α4βδ-expressing oocytes and only slightly higher intrinsic activity at the α4βδ GABAAR (Rmax values of 1–5% of GABA Rmax). However, the compound robustly potentiated GABA EC10-evoked responses through the two receptors (Fig. 5A). Conversely, etomidate (100 μM) was a pronounced agonist at the α4βδ GABAAR, evoking a response ~4-fold higher than the GABA Rmax at the receptor (Fig. 5B). Although the fact that we only studied the effects of a single high etomidate concentration (100 μM) in these recordings combined with its reported bell-shaped concentration-response relationships at other GABAARs (Belelli et al., 1997; Hill-Venning et al., 1997) preclude us from drawing conclusions regarding whether etomidate exhibits differential modulatory potencies or efficacies at the three α4βδ receptors, the qualitative nature of its modulation of the receptors can be extracted from the data. Analogously to methaqualone, etomidate is a fairly pure PAM at α4βδ and a superagonist at the α2βδ receptor, whereas its PAM activity at the α4βδ GABAAR contrasts the inactivity of methaqualone at this subtype (at concentrations up to 300 μM).

**Putative Binding Modes of Etomidate, Loreclezole, and Methaqualone.** All in all, the results outlined above indicate that methaqualone acts through the same transmembrane β+ωγ− interface in the GABAAR complex targeted by etomidate, the anticonvulsant drug loreclezole, and several other modulators. An analysis of the physical-chemical properties of etomidate, loreclezole, and methaqualone shows that the three compounds share notable structural similarities. Both etomidate and methaqualone comprise two hydrophobic moieties, as well as a carbonyl group and an aromatic nitrogen capable of acting as hydrogen bond acceptors (Fig. 6A). Loreclezole comprises one hydrophobic moiety as well as a vinylogous chlorine and a triazole ring system as a potential hydrogen bond acceptor (Fig. 6A). This similarity prompted us to compare the putative binding modes of the three modulators with the aim of defining one common pharmacophore.

In view of the relatively high functional potencies of etomidate, loreclezole, and methaqualone as GABAAR modulators, all three modulators are expected to bind to the receptor in a low-energy conformation. Thus, the three molecules were initially submitted to a stochastic conformational search to enumerate their respective low-energy conformations. In the
case of etomidate, the 2-phenethyl group adapted only one well defined conformation, and although three rotamers of the ester alkyl group was found the energy differences between these were not significant (∼1 kcal/mol). Methaqualone is also a highly rigid molecule, and its low-energy conformation was readily determined. The same was true for loreclezole, which adapted only one low-energy conformation. The low-energy conformations of the three molecules were superimposed based on the assumption that carbonyl groups of etomidate and methaqualone and the vinylogous chlorine of loreclezole dictate the binding modes of the respective compounds in the putative shared site (Fig. 6B). From this overlay, it is clear that the ester alkyl group of etomidate, the 2,4-dichlorophenyl ring of loreclezole, and the fused phenyl ring of methaqualone occupy the same area of space (designated hydrophobic pocket P1 in Fig. 6A). The 2-phenethyl group of etomidate and the N-phenyl group of methaqualone are oriented in the same area of space (designated pocket P2 in Fig. 6A). In this area, loreclezole comprises a triazole ring, which in comparison with the corresponding moieties in etomidate and methaqualone is less hydrophobic. Thus, the P2 pocket may be capable of accommodating the binding of ring systems with quite different physicochemical properties. Finally, the aromatic nitrogen atoms in the three molecules do not align perfectly in this superimposition; however, reorganization of the water molecules in the binding pocket (induced fit) could possibly adjust for the differences in hydrogen bond donating trajectories of the respective nitrogen atoms. Thus, the in silico study seems to support the hypothesis that etomidate, loreclezole, and methaqualone could bind to a common site in the transmembrane interface of the GABA\(_A\)R, although it should be noted that the superimposition of etomidate and methaqualone is more successful than the loreclezole/etomidate and loreclezole/methaqualone superimpositions.

**Screening of Methaqualone at Other Putative CNS Targets**

The possible existence of other CNS targets for methaqualone than GABA\(_A\)Rs was investigated in an elaborate screening of the compound at a total of 50 recombinant neurotransmitter receptors and transporters and at native GABA\(_A\)Rs and ionotropic glutamate receptors in rat brain homogenates, a selection that includes numerous key targets for known psychotropic drugs and psychostimulants. For most of these targets, the putative activity of methaqualone was assessed in competition binding assays (performed by PDSP), where radioligand concentrations near or at the \(K_D\) value for the specific target in these assays was used to facilitate the detection of both inhibition and potentiation of radioligand binding by the test compound. Methaqualone (30 μM) did not display significant modulation (neither potentiation or inhibition) of radioligand binding to a wide range of serotonin, dopamine, norepinephrine, histamine, acetylcholine, glutamate, opioid, cannabinoid, and sigma receptors or at the three monoamine transporters in these assays (Table 2). Furthermore, the compound was inactive at concentrations up to 1 mM when tested in functional assays at the other plasma membrane-bound targets for GABA: the GABA\(_B\) receptors and GABA transporters (Table 2).

The inability of 30 μM methaqualone to compete with \[^{3}H\]muscimol and \[^{3}H\]flunitrazepam binding to rat brain
TABLE 2
Pharmacologic properties of methaqualone at various central nervous system targets
The binding affinities for methaqualone at numerous targets in a competition binding assays (using radioligand concentrations near or at the $K_0$ value for the specific target) were determined by National Institute of Mental Health’s PDSP. The $IC_{50}$ values obtained for methaqualone in the binding assays are given in micromolar, and percent inhibition or percent potentiation of radioligand binding at 30 $\mu$M methaqualone is given in parentheses (positive and negative values represent percent inhibition and percent potentiation of control, respectively). An inhibition of $>50\%$ is considered significant by the PDSP. The data are based on four independent determinations. The functional properties of methaqualone at selected transporters and receptors were determined in in-house functional assays and are indicated by the # symbol. The $IC_{50}$ and $EC_{50}$ values obtained for methaqualone in these functional assays are given in micromolar.

<table>
<thead>
<tr>
<th>Target</th>
<th>Assay</th>
<th>$IC_{50}$ [µM] (%) Inhibition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serotonin</td>
<td><img src="image1.png" alt="Image" /></td>
<td><img src="image2.png" alt="Image" /></td>
</tr>
<tr>
<td></td>
<td><img src="image3.png" alt="Image" /></td>
<td><img src="image4.png" alt="Image" /></td>
</tr>
<tr>
<td></td>
<td><img src="image5.png" alt="Image" /></td>
<td><img src="image6.png" alt="Image" /></td>
</tr>
<tr>
<td></td>
<td><img src="image7.png" alt="Image" /></td>
<td><img src="image8.png" alt="Image" /></td>
</tr>
<tr>
<td>Dopamine</td>
<td><img src="image9.png" alt="Image" /></td>
<td><img src="image10.png" alt="Image" /></td>
</tr>
<tr>
<td></td>
<td><img src="image11.png" alt="Image" /></td>
<td><img src="image12.png" alt="Image" /></td>
</tr>
<tr>
<td></td>
<td><img src="image13.png" alt="Image" /></td>
<td><img src="image14.png" alt="Image" /></td>
</tr>
<tr>
<td></td>
<td><img src="image15.png" alt="Image" /></td>
<td><img src="image16.png" alt="Image" /></td>
</tr>
<tr>
<td></td>
<td><img src="image17.png" alt="Image" /></td>
<td><img src="image18.png" alt="Image" /></td>
</tr>
<tr>
<td>Acetylcholine</td>
<td><img src="image19.png" alt="Image" /></td>
<td><img src="image20.png" alt="Image" /></td>
</tr>
<tr>
<td></td>
<td><img src="image21.png" alt="Image" /></td>
<td><img src="image22.png" alt="Image" /></td>
</tr>
<tr>
<td></td>
<td><img src="image23.png" alt="Image" /></td>
<td><img src="image24.png" alt="Image" /></td>
</tr>
<tr>
<td></td>
<td><img src="image25.png" alt="Image" /></td>
<td><img src="image26.png" alt="Image" /></td>
</tr>
<tr>
<td>Histamine</td>
<td><img src="image27.png" alt="Image" /></td>
<td><img src="image28.png" alt="Image" /></td>
</tr>
<tr>
<td></td>
<td><img src="image29.png" alt="Image" /></td>
<td><img src="image30.png" alt="Image" /></td>
</tr>
<tr>
<td></td>
<td><img src="image31.png" alt="Image" /></td>
<td><img src="image32.png" alt="Image" /></td>
</tr>
<tr>
<td></td>
<td><img src="image33.png" alt="Image" /></td>
<td><img src="image34.png" alt="Image" /></td>
</tr>
<tr>
<td></td>
<td><img src="image35.png" alt="Image" /></td>
<td><img src="image36.png" alt="Image" /></td>
</tr>
<tr>
<td></td>
<td><img src="image37.png" alt="Image" /></td>
<td><img src="image38.png" alt="Image" /></td>
</tr>
<tr>
<td>GABA</td>
<td><img src="image39.png" alt="Image" /></td>
<td><img src="image40.png" alt="Image" /></td>
</tr>
<tr>
<td></td>
<td><img src="image41.png" alt="Image" /></td>
<td><img src="image42.png" alt="Image" /></td>
</tr>
<tr>
<td></td>
<td><img src="image43.png" alt="Image" /></td>
<td><img src="image44.png" alt="Image" /></td>
</tr>
<tr>
<td>Glutamate</td>
<td><img src="image45.png" alt="Image" /></td>
<td><img src="image46.png" alt="Image" /></td>
</tr>
<tr>
<td></td>
<td><img src="image47.png" alt="Image" /></td>
<td><img src="image48.png" alt="Image" /></td>
</tr>
<tr>
<td></td>
<td><img src="image49.png" alt="Image" /></td>
<td><img src="image50.png" alt="Image" /></td>
</tr>
<tr>
<td></td>
<td><img src="image51.png" alt="Image" /></td>
<td><img src="image52.png" alt="Image" /></td>
</tr>
<tr>
<td></td>
<td><img src="image53.png" alt="Image" /></td>
<td><img src="image54.png" alt="Image" /></td>
</tr>
</tbody>
</table>

CGP 12177, 4-(3-(tert-butylamino)-2-hydroxypropoxy)-1,3-dihydrobenzimidazol-2-one; CP55940, 2-(1R,2R,5R,10R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl-3-(5-2-methyloctan-2-yl)phenol; GR125743, N-[4-methoxy-3-[4-methylpiperazin-1-yl]phenyl]-3-methyl-4-(pyridin-4-yl)benzamide; h, human; LY278584, 1-methyl-N-[4-[1R,3S]-8-methyl-8-azacyclo[3.2.1]octan-3-yl]methyl[1H]pyrazolo[4,3-d]pyrimidin-4-ylmethanamine-3-carboxamide; m, mouse; PK11195, N-(butan-2-yl)-1-[3-methyl-4-phenylquinoline-3-carboxamide; r, rat; SCH23390, 8-chloro-3-methyl-5-phenyl-1,2,4,5-tetrahydro-3-benzazepin-7-ol; U69593, N-methyl-2-phenyl-N-[3R,7S,8S]-7-gymnolind-1-yl-1-oxazepin-4,5(4H)decan-8-yllacetamide; WIN35428, methyl 1S,3S,AS,3R-1-[4-fluorophenyl]-8-methyl-8-azacyclo[3.2.1]octane-4-carboxylate.
tissue in the PDSP screening is in concordance with the binding site proposed for the modulator at GABA\(_A\)Rs in this study. On the other hand, the insignificant modulation exerted by the compound on radioligand binding to native GABA\(_A\)Rs in these assays could be argued to contrast with the augmentation of radioligand binding to the orthosteric and the benzodiazepine binding sites in native GABA\(_A\)Rs previously reported for other allosteric modulators of these receptors. Most notably in connection with methaqualone, both etomidate and lorazepole have been reported to enhance \(\[^{3}H\]muscimol and \(\[^{3}H\]flunitrazepam binding to rat brain tissue (Quast and Brenner, 1983; Slany et al., 1995; Ghiani et al., 1996; Xue et al., 1996; Zhong and Simmonds, 1997; Sarantis et al., 2008). However, not all modulators targeting a common binding site may necessarily be capable of modulating ligand binding to other sites in the receptors. Furthermore, the reported degrees of radioligand binding enhancement induced by etomidate and lorazepole in these studies vary considerably, and the modulation has not been observed in all studies (Green et al., 1996). Thus, specific assay conditions seem to influence whether putative modulation of binding is detected in a radioligand binding assay.

An obvious caveat connected to the use of the competition binding assays in this screening is that not all ligands targeting an allosteric site in a certain target necessarily will compete with or modulate orthosteric radioligand binding to it. However, most targets assayed by radioligand binding in the screening were family A 7-transmembrane receptors (i.e., 37 of 48), and to our knowledge few (if any) allosteric modulators of these receptors have been reported not to affect orthosteric radioligand binding (Keov et al., 2011). Hence, although we cannot completely exclude the possibility that methaqualone could target an allosteric site in one (or several) of the receptors, the inactivity of the drug in the binding assays is likely to be a true reflection of its pharmacology at these receptors. In contrast, identification of ligands targeting multidomain receptor complexes such as the GABA\(_A\)Rs or ionotrophic glutamate receptors in a competition binding assay is likely to be more dependent on the specific radioligand and the experimental conditions used. Thus, the observed lack of effect of methaqualone on radioligand binding to these receptors should be seen only as a demonstration of the compound not binding to the specific site in the receptor complex targeted by the radioligand.

**Multiparametric Description of the Effects of Methaqualone on Cortical Network Activity In Vitro**

To investigate the effects of methaqualone at native GABA\(_A\)Rs and on neuronal network activity, we analyzed the modulation exerted by the drug at the spontaneous activity pattern of primary neuronal networks from murine frontal cortex grown on MEA neurochips by multiparametric data analysis. This technology has previously been used extensively for neurotoxicity studies (Gramowski et al., 2006b; Johnstone et al., 2010; Novellino et al., 2011) but also for functional phenotypic screening of drugs (Gramowski et al., 2004, 2006a; Parenti et al., 2013). The 204 activity-describing parameters calculated based on the spike trains from these recordings can be divided into four categories. “General Activity” parameters represent global network activity descriptors such as spike rate, burst rate, percentage of spikes in bursts and burst period; “Burst Structure” parameters describe the internal structure of spikes within a high-frequency spiking phase (e.g., spike frequency in bursts, spike rate in bursts, spike density), as well as the overall burst structure (e.g., duration, area, plateau); “Oscillatory Behavior” parameters are the standard deviations associated with main general activity and burst structure parameters and illustrate the regularity of bursting events within experimental episodes, with higher values indicating less regular general activity or less regular burst structure. Finally, the “Synchronicity” parameters include those representing the coefficient of variation over the network, thus reflecting the level of synchronization among the neurons. Representative spike raster plots and some of the aforementioned extractable parameters from these recordings are given in Fig. 7.
Concentration-Effect Relationships for Methaqualone and Other GABAAR Modulators in the Network Recordings. The overall profile of methaqualone in the recordings reflected in the 60 best-describing parameters was quite characteristic for a CNS depressant (Figs. 8 and 9). Application of the modulator in concentrations found to elicit significant effects at the recombinant GABA\(_\text{ARs}\) in the TEVC recordings (1–100 μM) resulted in significantly reduced spike and burst rates and increased the interval between bursts as well as the average burst period. Moreover, burst sizes were significantly reduced by the presence of these methaqualone concentrations (e.g., decreases in burst duration, burst area, and burst amplitude) (Figs. 8 and 9). The decreased variability observed for several of the burst structure parameters (e.g., burst area S.D. and burst spike number S.D.) indicated a more regular burst structure, whereas the overall bursting activity was observed to be more irregular (increase in burst rate S.D., interburst interval S.D., event period S.D.). Finally, increased network variability (e.g., burst rate CVnet and other CVnet parameters, decreased SynShare, the average number of units involved in population bursts) indicative of decreased synchronization within the network.

Fig. 8. Summary of the changes induced by methaqualone, DS2, diazepam, phenobarbital, and etomidate on cortical network activity in vitro. The heat maps present the significant changes in 60 activity-describing parameters from four defined categories arising from eight or nine cumulatively increasing concentrations of the five modulators (concentrations are given in molar). The colors encode statistically significant modulator-induced changes (increases or decreases) in parameters relative to native activity (no drug, 100%).

Concentration-Effect Relationships for Methaqualone and Other GABA\(_\text{AR}\) Modulators in the Network Recordings.
was observed at these modulator concentrations (Figs. 8 and 9). Interestingly, submicromolar concentrations of methaqualone also mediated significant effects on network activity although these were very subtle (Figs. 8 and 9).

The functional characteristics of methaqualone in the MEA recordings were compared with those exhibited by four other GABA<sub>A</sub>R modulators: the benzodiazepine diazepam, the barbiturate phenobarbital, the general anesthetic etomidate, and DS2, a selective PAM of δ-containing GABA<sub>A</sub>Rs (Wafford et al., 2009). The multiparametric effects mediated by diazepam, etomidate, and phenobarbital at the cortical networks were quite similar to those induced by methaqualone, the different concentration-response relationships displayed by the four modulators being easily reconcilable with their different potencies as a GABA<sub>A</sub>R PAMs (Figs. 8 and 9). However, while the qualitatively trend in the changes induced by methaqualone, diazepam, etomidate, and phenobarbital was the same for most parameters, some interesting differences were observed. For example, high or saturating concentrations of etomidate or methaqualone induced more pronounced changes in some of the “General Activity”, “Burst Structure”, and “Oscillatory Behavior” parameters than high or saturating concentrations of phenobarbital or diazepam (Fig. 8).

The general effects of DS2 on cortical network activity were much more subtle than those produced by the four other modulators, but most of the changes induced by this PAM were characterized by the same qualitative directions of parameter changes (Figs. 8 and 9).
**In Vivo Exposure and Efficacy of Methaqualone in Seizure Threshold and Motor Coordination Assays**

To investigate to what extent the in vitro properties displayed by methaqualone at GABA\(\alpha\)Rs correlated with its in vivo efficacy, exposure studies of the drug were combined with testing in MEST and beam-walk assays in mice using diazepam as a reference GABA\(\alpha\)R modulator (Fig. 11).

In preliminary exposure studies, plasma and brain concentrations of methaqualone were determined 15, 30, 60, and 120 minutes after subcutaneous administration of 10 mg/kg of the drug, and since both concentrations peaked at 60 minutes, this study design was used for the subsequent experiments. After administration of 10-, 30-, and 100-mg/kg doses of methaqualone, plasma concentrations of the drug were determined to 2.79 ± 0.57, 12.3 ± 0.93, and 26.7 ± 0.63 \(\mu\)g/ml, respectively, and brain concentrations to 0.71 ± 0.10, 4.1 ± 0.23, and 16.1 ± 0.27 \(\mu\)g/g, respectively (means ± S.E.M.; \(n = 3\)). Since the levels of free (unbound) fraction of methaqualone in mouse brain homogenates were determined to be 13%, corresponding unbound concentrations of methaqualone in brain were estimated at 0.37 ± 0.05, 2.14 ± 0.12, and 8.38 ± 0.14 \(\mu\)g/M for the 30-, 100-, and 100-mg/kg doses, respectively (Fig. 11A). Plasma and brain concentrations of the reference drug diazepam were not determined in this study; however, a previous study has found subcutaneous administration of 3 mg/kg of diazepam in mice to produce a total brain concentration of 400 ng/g (30 minutes after administration) (Doran et al., 2005), and we have determined the fraction of free (unbound) diazepam in mouse brain to be 5%. Extrapolating from this finding, the 0.3-, 1-, and 3-mg/kg diazepam doses used in this study (Fig. 11B) would correspond to brain free diazepam concentrations of approximately 4, 15, and 40 nM, respectively.

Both methaqualone and diazepam displayed significant effects in the two animal models. Whereas subcutaneous administration of 100 mg/kg of methaqualone significantly increased seizure threshold in the animals in the MEST assay, administration of 30 or 100 mg/kg of methaqualone resulted in significantly increased numbers of slips and falls in the beam-walk assay (Fig. 11A). Analogously, diazepam and other benzodiazepines in these models induced significant sedative or ataxia effects at lower doses than those required to produce significant anticonvulsant effects (Fig. 11B and unpublished data). The doses of the two drugs needed to induce sedative or ataxia and anticonvulsant effects could seem somewhat high at first glance. However, it is well documented that readouts in rodents and humans on drug treatment do not always correlate, something that has been ascribed to the substantially faster hepatic clearance compared with the profiles of each of the reference compounds (i.e., the averaged effects induced by multiple concentrations of the reference compound). With the exception of the classic antipsychotic drug chlorpromazine and the anti-depressant amitriptyline, the database compounds giving rise to effects exhibiting the highest similarities to those mediated by methaqualone (1–100 \(\mu\)M) were GABA\(\alpha\)R PAMs (etomidate, diazepam, thioental, clonazepam), NMDA receptor antagonists (MK801 (55,10\(R\)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate), memantine), and other CNS depressants (valproate, retigabine) (Fig. 10).
and drug metabolism in rodents (Lave et al., 1999; Sharma and McNeill, 2009).

Discussion
Investigations into the mechanisms of action of old CNS drugs hold interesting perspectives. Although a drug may have been shelved for good reasons, new insights into the molecular basis for its clinical efficacy can open new avenues of drug development, as exemplified by the current interest in ketamine as a lead for novel antidepressants (Sanacora and Schatzberg, 2015). Moreover, these explorations can shed light on previous observations for the drug and its target and could potentially reinvent the drug as a useful pharmacologic tool. In the present study, the notorious past and elusive mode of action of methaqualone (and other quaaludes) prompted us to explore the molecular basis underlying its therapeutic and recreational effects.

Methaqualone Is a Multifaceted GABAAR Modulator.
Methaqualone was found to be a pan-active GABAAR modulator exhibiting activity at 12 of 13 GABAAR subtypes (Table 1). Albeit a relatively pure PAM at most of these receptors, methaqualone exhibited everything from inactivity over negative or positive modulation to pronounced agonism within this selection of subtypes. Moreover, the nature of its potentiation of $\alpha_1\beta_2\delta\gamma_2\sigma$ and $\alpha\beta_2\delta/\alpha\beta_3\delta$ signaling differed, as it exclusively modulated GABA potency at the $\alpha\beta\gamma$ receptor, whereas it increased both GABA potency and efficacy at the $\alpha\beta\delta$ receptor. The presence of $\gamma_2$ or $\delta$ in the GABAAR was clearly not a prerequisite for methaqualone-mediated modulation, but these differential PAM characteristics nevertheless must be ascribed to the distinct functional properties of $\alpha\beta\gamma$ and $\alpha\beta\delta$ receptors. Whereas the remarkable high-efficacious direct activation of the $\alpha\beta\delta$ receptor mediated by methaqualone could be a reflection of true allosteric agonism, we cannot exclude that it could arise from potentiation of the pronounced spontaneous activity of this receptor, analogously to the mechanism proposed to underlie the apparent agonist displayed by DS2 at this receptor in a recent study (Jensen et al., 2013). The fact that etomidate also displays superagonism at $\alpha\beta_3\delta$ seems to support this latter hypothesis (Fig. 5).

Conversely, the inability of both modulators to potentiate the constitutive activity exhibited by the $\alpha\beta\delta$ receptor suggests that they could possess true intrinsic agonist activity at $\alpha\beta_3\delta$ or, alternatively, that the molecular basis for the spontaneous activity of $\alpha\beta_1\delta$ may differ from that of $\alpha\beta_3\delta$ (Fig. 5).

![Fig. 10.](#) Similarity analysis of the effects of methaqualone at cortical network activity. Top 10 ranks of the most phenotypically similar functional profiles of 69 reference compounds from the NeuroProof database (listed in Table 3) ranked based on the similarity score for methaqualone at concentrations ranging from 1 to 100 μM. Data for the methaqualone concentrations 1, 10, and 100 nM are given in shaded colors. The concentration-response profiles of the 69 reference compounds were used for training the classifier, and the methaqualone data sets were classified per concentration (10 per concentration). Table values correspond to similarity score per concentration (e.g., at 100 μM methaqualone, 8% of its data sets were classified as etomidate, 4% as diazepam, 12% as chlorpromazine, and so forth). High values reflect high functional phenotypic similarity between reference compound effects and methaqualone effects.

![Fig. 11.](#) Sedative or ataxic effects and anticonvulsant efficacy of methaqualone (A) and diazepam (B) in beam walk and MEST assays in mice. Data are given as average slips and falls (mean ± S.E.M.) and by the average current threshold (mean ± S.E.M.), respectively. *P < 0.05 analysis of variance and post hoc Dunnett’s test. HPBc; hydroxypropyl-β-cyclodextrin.
The comparable functional potencies displayed by methaqualone as PAM, NAM, or agonist at the various GABA\(_A\)Rs suggest that the modulator targets a uniform binding site in the receptors, a hypothesis further supported by the complete reversal of its modulatory properties at the \(\alpha\beta\delta\) and \(\alpha\beta\gamma\) receptors brought on by \(\beta_1\)-S265N and \(\beta_2\)-N265S mutations (Fig. 4, B and C). Thus, the diverse functionalities of methaqualone are more likely to arise from different energy barriers underlying allosteric transitions in the respective subtypes than from the modulator targeting different sites or having substantially different binding modes in the receptors. Although the inactivity of methaqualone at \(\alpha\beta\gamma\delta\) would constitute an outlier in this scenario if rooted in low affinity, the compound could also be envisioned to act as a neutral ligand (or silent allosteric modulator) at this subtype. We will refrain from further speculations about this, however, not having investigated the basis for the lack of modulation at this subtype. Analogously to the notion of methaqualone exerting its multifaceted pharmacology through a uniform site in the GABA\(_A\)Rs, some benzodiazepine-site ligands display functional selectivity at \(\alpha_1\beta_2\gamma_2\delta\) receptors (Dawson et al., 2006; de Lucas et al., 2015), and allosteric modulators of other receptor types have also been shown to mediate subtype-specific modulation (Mathiesen et al., 2003; Marlo et al., 2009; Costa et al., 2010).

The bell-shaped concentration-response curves and rebound currents obtained for methaqualone at the GABA\(_A\)Rs are very similar to those observed for other PAMs/agon-PAMs acting through the transmembrane receptor domains (Fig. 1, C and D) (Hill-Venning et al., 1997; Wooltorton et al., 1997; Halliwell et al., 1999; Feng and Macdonald, 2004; Feng et al., 2004; Khom et al., 2007). In several of these cases, the submaximal potentiation observed at high modulator concentrations has been attributed to the existence of a low-affinity open-channel block site, with the rebound currents arising from the rapid unbinding of the modulator from this site (Wooltorton et al., 1997; Halliwell et al., 1999; Feng et al., 2004; Khom et al., 2007). This also seems a plausible explanation for methaqualone, although the submaximal potentiation at high modulator concentrations also could be caused by increased receptor desensitization.

The Methaqualone Binding Site. Solid experimental evidence indicates that methaqualone does not act through the benzodiazepine, barbiturate, or neurosteroid binding sites in the GABA\(_A\)R (Fig. 3). We propose that the key importance of \(\beta\)-subunit identity and of \(\beta\)-residue 265 for the functionality of methaqualone constitutes a strong case for the transmembrane \(\beta^{4+}\gamma\) interface as the targeted receptor region. In contrast, there are compelling reasons to be cautious when speculating about the exact location of the binding site within this interface. Allosteric modulators bind quite differently to allosteric sites and therefore appear to interact with the GABA\(_A\)R using different pathways to the membrane. This is expected to arise from the substantial differences in the pharmacologic and therapeutic properties of GABA\(_A\)R modulator classes (Fig. 10; Table 3). The high-ranking of chlorpromazine constitutes a notable exception in this respect. Although micromolar chlorpromazine concentrations have been reported to modulate GABAergic currents in hippocampal neurons (Mozrzymas et al., 1999a,b), it is highly promiscuous drug with potent activity at numerous receptors, transporters, and ion channels, and thus its effects on neuronal network activity are unlikely to arise from several other mediators.

Correlation between In Vitro GABA\(_A\)R Activity and In Vivo Efficacy of Methaqualone. As discussed above, the negligible activity displayed by methaqualone at a plethora of neurotransmitter targets in the screening and its effects on cortical network activity in the MEA recordings all in all seem to indicate that it is a fairly selective GABA\(_A\)R modulator (Figs. 7–10; Table 2). This finding prompted us to investigate whether its GABA\(_A\)R activity could account for its in vivo efficacy. The estimated free (unbound) methaqualone concentrations in mouse brain arising from in vivo effective doses (2–8 \(\mu\)M) were in the very low end of the effective concentration range for the modulator at GABA\(_A\)Rs in the TEVC recordings. This apparent mismatch is unlikely to arise from substantially different pharmacologic properties of methaqualone at recombinant human and native rodent GABA\(_A\)Rs, just as it seems improbable that its in vivo effects are mediated through another target. Instead, it could simply be a reflection of allosteric GABA\(_A\)R modulators being efficacious in vivo at low levels of receptor occupancy.
Interestingly, the estimated free concentrations of diazepam in mice brains produced by in vivo effective doses (4–40 nM) were also substantially lower than the functional potency of the benzodiazepine at recombinant αβγ GABAARs (EC\textsubscript{50} ~100 nM). In this light, our data could support the notion of GABAARs as the key mediators of the in vivo effects of methaqualone.

**Conclusion.** The present delineation of the molecular basis for the behavioral effects of methaqualone does more than confirm what has been assumed for decades: that the drug mediates these effects through GABAARs. Methaqualone exhibits distinct functional properties at the GABAARs compared with other allosteric modulators, and it mediates these through a different mechanism than the barbiturates and benzodiazepines that it historically has been lumped together with. It is tempting to speculate that these differences could contribute to the reported differences in the in vivo effects induced by methaqualone and classic CNS depressants. In any case, the multifaceted functionality of methaqualone at GABAARs seems to be at the root of its clinical efficacy, as well as the addiction liability and recreational misuse associated with the drug.

**Acknowledgments**

The authors thank Dr. P. J. Whiting and Merck, Sharpe, and Dohme Research Laboratories for the generous gifts of the human GABA\(_R\) cDNAs, and Dr. S. Mennerick for kind advice.

**Authorship Contributions**

Participated in research design: Hammer, Bader, Schroeder, Bastlund, Gramowski-Voß, Jensen.

Conducted experiments: Hammer, Bader, Ehnter, Bundgaard, Bunch, Jensen.

Performed data analysis: Hammer, Bader, Ehnter, Hoestgaard-Jensen, Bastlund, Jensen.

Wrote or contributed to the writing of the manuscript: Hammer, Bader (with contributions from Ehnter, Bundgaard, Bunch, Bastlund).

**References**


